Is ARS Pharmaceuticals, Inc (SPRY) overvalued? · rev $89.1M
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
This page asks whether ARS Pharmaceuticals, Inc (SPRY) looks expensive on cached numbers — not a short thesis.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
SPRY currently screens at market cap $983.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SPRY 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SPRY stock page for the full model, not this heading.
Not investment advice.